Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Keravision(kera) -- Ignore unavailable to you. Want to Upgrade?

To: backspin who wrote (211)	8/12/1999 6:37:00 PM
From: Phil	Respond to of 338

backspin, I don't think your first sentence matches your second. Because of the advantages which ICRS offers over LASIK, Intacs will be chosen by the surgeons. I asked two laser clinics that also do Intacs for information. Going by the clinic's comparison chart, Intacs are listed as the procedure if your vision is in their range. Lasik was listed as a treatment only for eyes beyond -3.0. Also, I wouldn't rely too much on the major investment in equip that the 29% of ophthos who do Lasik have made. They can pay off that machine just as easily with Intacs procedures as they can with VISX procedures. They make just as much profit. If the patient is within the range of Intacs, and knows the options, the patient is going to choose Intacs over laser 99,999 times out of 100,000. So why would an idoc run the risk of a lawsuit based on lack of informed consent??? It's simple, the idoc won't. As to your final point, KERA is now good till 12/2001.That is well more than a couple of quarters. Best to you, Phil